{"id":192581,"name":"BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.","slug":"boehringer-ingelheim-pharmaceuticals-inc","state":"CT","description":"pharmaceutical company","totalSpending":1510000,"filings":29,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":100000},{"year":2020,"income":200000},{"year":2021,"income":150000},{"year":2022,"income":250000},{"year":2023,"income":200000},{"year":2024,"income":260000},{"year":2025,"income":150000}],"firms":["THORN RUN PARTNERS"],"lobbyists":["ANDREW ROSENBERG","GARY PALMQUIST","CHARLES THOMAS","BEAU SCHUYLER","PAUL BOCK","HARRIET MELVIN"],"issues":["HCR","FOR","MMM",null],"sampleDescriptions":["Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.","Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.","Rebates for dual eligible and low-income subsidy population in Medicare Part D. Non-Interference. Implementation of the 21st Century Cures Act (P.L.114-255). ADUFA Reauthorization.\nPart D coverage gap and the Medicare reimbursement of biosimilars; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).","Value Based Contracting.\nBrand safety and security.","Legislation related to CFIUS and FARA including issues related to critical technologies and export controls;\nS.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017;\nS.2482, Foreign Agents Registration Amendments Act of 2018.","Rebates for dual eligible and low-income subsidy population in Medicare Part D.\nNon-Interference.\nImplementation of the 21st Century Cures Act (P.L.114-255).\nADUFA Reauthorization.\nPart D coverage gap and the Medicare reimbursement of biosimilars.","Issues related to Value Based contracting, brand safety and security.","Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. \nMedicare reimbursement for biosimilars.","Issues related to Value Based contracting, brand safety and security.\nIssues related to access to diabetes medicines; issues related to ICD-10 Coding for Breakthrough Therapy Designations; 2021 Labor, HHS Appropriations","Issues related to supply chain policy.\nIssues related to access to diabetes medicines; issues related to ICD-10 Coding for Breakthrough Therapy Designations; H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021","Issues related to supply chain policy.\nIssues related to ICD-10 Coding for Breakthrough Therapy Designations; H.R.7614 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021","Issues related to supply chain policy.\nMedicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions.","Issues related to supply chain policy.","Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Medicare reimbursement for biosimilars.","Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Medicare reimbursement for biosimilars. Issues related to biosimilar therapies. Issues related to Part D formularies.","Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Medicare reimbursement for biosimilars. Issues related to biosimilar therapies. Issues related to Part D formularies. Prescription Drug User Fee Act (PDUFA). H.R.5376 - Inflation Reduction Act of 2022.","Issues related to supply chain policy, prescription digital therapeutics.","Issues related to Medicare and Medicaid reimbursement for pharmaceuticals. Medicare reimbursement for biosimilars. Issues related to biosimilar therapies. Issues related to Part D formularies.â€Œ","Issues related to Senate HELP Committee investigation into inhalers. Policies related to creating incentives for innovation in the life sciences.","Policies related to creating incentives for innovation in the life sciences."],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}